Celularity Inc. CELU

Company Overview

Celularity Inc. is a U.S.-based biotechnology company focused on the development of cellular medicines, biomaterial products, and regenerative medicine technologies derived primarily from the human placenta. The company operates within the biotechnology, immunotherapy, and regenerative medicine industries, with a strategic emphasis on allogeneic cell therapies designed to treat cancer, infectious diseases, and degenerative conditions. Celularity’s primary revenue sources have included biomaterial product sales, licensing arrangements, collaborative agreements, and regenerative medicine-related commercial activities, while its therapeutic pipeline remains largely in the clinical and development stages.

The company traces its origins to research and commercialization initiatives associated with placental-derived cells and tissues developed under Celgene Corporation’s cellular therapeutics efforts. Celularity later became an independent company and entered public markets through a merger with a special purpose acquisition company in 2021. Its positioning has centered on the scalability and immunologic characteristics of placental-derived allogeneic therapies, which the company has described as potentially enabling off-the-shelf treatment approaches compared with patient-specific autologous therapies.

Business Operations

Celularity’s operations have historically been organized around cellular therapeutics, biomaterials, and regenerative medicine platforms. Its core therapeutic programs have included placental-derived natural killer (NK) cell therapies, T-cell therapies, and mesenchymal-like adherent stromal cell candidates. The company has also developed and commercialized biomaterial products derived from postpartum placental tissue for wound care, surgical applications, and regenerative medicine uses. Revenue generation has primarily come from product sales in biomaterials and from licensing and collaboration agreements tied to therapeutic development programs.

The company operates primarily in the United States, with research, manufacturing, and corporate functions centered domestically while maintaining international collaboration and distribution relationships. Celularity has controlled proprietary manufacturing capabilities and intellectual property related to placental-derived cell collection, processing, and cryopreservation technologies. Public disclosures have referenced collaborations and licensing relationships involving immunotherapy development and cell manufacturing activities, although some partnership details and commercial impacts remain limited in publicly available filings. Data regarding the long-term financial contribution of certain collaborations is inconclusive based on available public sources.

Strategic Position & Investments

Celularity’s strategic direction has focused on advancing allogeneic cell therapy platforms and expanding applications for placenta-derived technologies across oncology, infectious disease, and regenerative medicine. The company has invested in clinical-stage immunotherapy candidates, including NK-cell and genetically modified cellular therapies intended to support broader off-the-shelf treatment accessibility. Management has also emphasized manufacturing scale, cryopreservation technologies, and platform-based therapeutic development as competitive differentiators.

The company has pursued acquisitions, licensing arrangements, and technology investments aimed at strengthening its therapeutic pipeline and biomaterial portfolio. Public filings and investor materials have identified ongoing investment in next-generation cellular engineering capabilities and regenerative biomaterials. Celularity has also maintained interests in advancing biobanking and placental tissue-derived commercial applications. While management has communicated ambitions for broader platform commercialization, several pipeline programs remain subject to clinical validation and regulatory review, and future commercialization outcomes remain uncertain.

Geographic Footprint

Celularity is headquartered in Florham Park, New Jersey, and its principal operational footprint has been concentrated in the United States. The company’s manufacturing, research, and corporate infrastructure have primarily supported North American operations, including therapeutic development, biomaterial processing, and commercial distribution activities. Its biomaterial and regenerative medicine products have been marketed through healthcare channels serving hospitals, surgical centers, and wound care providers.

Internationally, Celularity has pursued collaborative relationships and distribution opportunities in selected foreign markets, though its operational scale outside the United States has remained comparatively limited relative to larger global biotechnology peers. The company’s strategic interests have included participation in broader international regenerative medicine and immunotherapy markets, but publicly available filings indicate that the majority of its assets, personnel, and revenue-generating operations remain U.S.-focused.

Leadership & Governance

Celularity’s leadership team has included executives with backgrounds in biotechnology, pharmaceuticals, cellular therapeutics, and healthcare commercialization. The company was founded with participation from figures associated with cellular medicine and regenerative therapeutics development, including former executives linked to Celgene’s cellular therapy initiatives. Leadership communications have consistently emphasized scalable allogeneic therapies, translational research, and integrated manufacturing capabilities as central strategic priorities.

Key executives and leadership figures identified in public filings and company disclosures include:

• Robert J. Hariri, M.D., Ph.D. – Founder and former Chief Executive Officer
• Nazim Ahmed – Chief Executive Officer
• Vladimir Bogin, M.D. – Chief Medical Officer
• Mark Augustine – former Chief Financial Officer
• Palak Patel – former Chief Business Officer

The company is governed by a board of directors and executive leadership structure typical of publicly traded biotechnology companies, with oversight responsibilities covering clinical development, regulatory compliance, financial reporting, and strategic partnerships. Governance practices and executive appointments have been disclosed through SEC filings, including annual reports, proxy statements, and investor presentations.